Page last updated: 2024-12-06

parvaquone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Parvaquone is an anti-cancer drug that is used to treat a type of cancer called Kaposi's sarcoma. It works by inhibiting the growth and spread of cancer cells. Parvaquone was first synthesized in the 1970s and has been studied extensively for its potential use in treating a variety of cancers. It has been shown to be effective in treating Kaposi's sarcoma, as well as other types of cancer, such as non-Hodgkin lymphoma. Parvaquone is currently being studied for its potential use in treating other diseases, such as malaria. Parvaquone is an important drug because it is effective in treating Kaposi's sarcoma, a cancer that is often difficult to treat. It is also being studied for its potential use in treating other diseases. The drug is particularly interesting because it targets the mitochondria, an organelle that is essential for the survival of all cells. By interfering with mitochondrial function, parvaquone can kill cancer cells without harming healthy cells. However, parvaquone can also have side effects, such as nausea, vomiting, and fatigue. '

parvaquone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	71825
CHEMBL ID	103124
CHEMBL ID	2105306
SCHEMBL ID	916441
SCHEMBL ID	16621117
MeSH ID	M0090644

Synonyms (35)

Synonym
nsc-631611
nsc631611
2-cyclohexyl-3-hydroxy-naphthalene-1,4-dione
2-cyclohexyl-3-hydroxynaphthoquinone
nsc278
nsc-278
2-cyclohexyl-3-hydroxy-1,4-naphthoquinone
4042-30-2
parvaquone
parvaquone [inn:ban]
parvaquonum [latin]
1,4-naphthalenedione, 2-cyclohexyl-3-hydroxy-
einecs 223-734-5
nsc 278
2-hydroxy-3-cyclohexyl-1,4-naphthoquinone
parvaquona [spanish]
CHEMBL103124
3-cyclohexyl-4-hydroxynaphthalene-1,2-dione
CHEMBL2105306
a2bh18685w ,
parvaquona
parvaquonum
unii-a2bh18685w
NCGC00345333-01
parvaquone [mi]
parvaquone [inn]
parvaquone [mart.]
JBFUOGRCSLVENL-UHFFFAOYSA-N
2-cyclohexyl-3-hydroxy-naphthalene-1.4-dione
SCHEMBL916441
SCHEMBL16621117
2-cyclohexyl-3-hydroxynaphthalene-1,4-dione
Q27273529
DTXSID00877991
3-cyclohexyl-4-hydroxy-1,2-dihydronaphthalene-1,2-dione

Research Excerpts

Dosage Studied

Excerpt	Relevance	Reference
" parva, menoctone cured all of 7 cattle at a total dosage of 10 mg/kg injected intravenously (i."	( Experimental therapy of theileriosis. McHardy, N, 1979)	0.26
" Imidocarb, at a dosage of 4 mg/kg of body weight, given IM at 72-hour intervals 4 times, was ineffective in eliminating B equi-carrier infection in 9 mature geldings."	( Imidocarb and parvaquone in the treatment of piroplasmosis (Babesia equi) in equids. Gipson, CA; Kuttler, KL; Zaugg, JL, 1987)	0.63

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay ID	Title	Year	Journal	Article
AID213066	In vitro concentration required to reduce the proportion of schizont infected cells in the culture to 50% of that of untreated control in the 48 hr incubation period	1981	Journal of medicinal chemistry, Mar, Volume: 24, Issue:3	In vitro activity of 2-alkyl-3-hydroxy-1,4-naphthoquinones against Theileria parva.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	26 (72.22)	18.7374
1990's	7 (19.44)	18.2507
2000's	3 (8.33)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	26.21 (24.57)
Research Supply Index	3.64 (2.92)
Research Growth Index	4.06 (4.65)
Search Engine Demand Index	31.58 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (26.21)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (2.78%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	35 (97.22%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
albendazole [no description available]	1.98	1	0	aryl sulfide; benzimidazoles; benzimidazolylcarbamate fungicide; carbamate ester	anthelminthic drug; microtubule-destabilising agent; tubulin modulator
diminazene Diminazene: An effective trypanocidal agent.. diminazene : A triazene derivative that is triazene in which each of the terminal nitrogens is substituted by a 4-carbamimidoylphenyl group.	1.96	1	0	carboxamidine; triazene derivative	antiparasitic agent; trypanocidal drug
furosemide Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.	2.42	2	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
thymidine [no description available]	1.96	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	3.07	5	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
imidocarb Imidocarb: One of ANTIPROTOZOAL AGENTS used especially against BABESIA in livestock. Toxicity has been reported.	7.39	2	0	ureas	antiprotozoal drug
menoctone [no description available]	7.65	3	0
decamethrin decamethrin: pyrethroid insecticide; RN given refers to cpd without isomeric designation; structure	2	1	0	aromatic ether; cyclopropanecarboxylate ester; nitrile; organobromine compound	agrochemical; antifeedant; calcium channel agonist; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; pyrethroid ester insecticide
halofuginone [no description available]	3.07	5	0	quinazolines
buparvaquone buparvaquone: used in therapy of theileriasis; structure given in first source	3.36	7	0
naphthoquinones Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.	11.25	35	1
diminazene aceturate diminazene diaceturate : An N-acetylglycinate salt resulting from the reaction of diminazene with 2 mol eq. of N-acetylglycine.	1.96	1	0	N-acetylglycinate salt	antiparasitic agent; trypanocidal drug
piperidines Piperidines: A family of hexahydropyridines.	2.66	3	0
oxytetracycline, anhydrous Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.	3.22	6	0
pyrethrins [no description available]	2	1	0

Condition	Relationship Strength	Studies	Trials
Corridor Disease [description not available]	6.06	29	1
Parasitemia The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)	2.41	2	0
Bovine Diseases [description not available]	2.68	3	0
Edema, Pulmonary [description not available]	2.02	1	0
Pulmonary Edema Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening.	2.02	1	0
Leukocytopenia [description not available]	1.96	1	0
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	1.96	1	0
Anguilluliasis [description not available]	1.98	1	0
Strongyloidiasis Infection with nematodes of the genus STRONGYLOIDES. The presence of larvae may produce pneumonitis and the presence of adult worms in the intestine could lead to moderate to severe diarrhea.	1.98	1	0
Equine Diseases [description not available]	2.38	2	0
Pyrexia [description not available]	2	1	0
Tick Infestations Infestations with soft-bodied (Argasidae) or hard-bodied (Ixodidae) ticks.	2	1	0
Fever An abnormal elevation of body temperature, usually as a result of a pathologic process.	7	1	0
Babesia Infection [description not available]	2.67	3	0
Canine Diseases [description not available]	2.01	1	0
Protozoan Infections, Animal Infections with unicellular organisms formerly members of the subkingdom Protozoa. The infections may be experimental or veterinary.	2.37	2	0
Histomoniasis [description not available]	2.37	2	0
Cat Diseases Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used.	2.37	2	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	1.96	1	0
Complications, Infectious Pregnancy [description not available]	1.97	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	1.97	1	0
Ovine Diseases [description not available]	1.97	1	0

chemdatabank.com